What Is Next Best Action (NBA) in Pharma?
Next best action (NBA) in pharma is a decision framework that uses HCP signals to recommend which HCP to engage, through which channel, and when.
Next best action (NBA) in pharma is a decision framework that uses HCP signals to recommend which HCP to engage, through which channel, and when.
Meld u aan om de nieuwste inzichten en updates over technologie, AI & data-analyse, datawetenschap en innovaties van Polestar Analytics te ontvangen.
Next best action (NBA) in pharmaceutical industry is the decision layer that turns HCP signals into a specific recommendation for the field. It reads prescribing behaviour, engagement history, and channel response, then answers these questions at once: which HCP to engage, through which channel, and when. Next best action in pharma replaces static call plans with a per-HCP, per-week decision the rep can act on.
Most pharma commercial teams no longer struggle to collect HCP data. CRM logs, prescribing data, patient-journey signals and third-party healthcare data are already flowing in. The struggle is deciding what the field should do with all of it. Next best action in pharmaceutical marketing closes that gap, converting scattered signals into a sequenced action for a specific HCP.
That distinction matters more as HCP engagement grows more fragmented. Deloitte's Life Sciences and Health Care Outlook found that 32% of biopharma executives consider customer engagement needs significant, reinforcing that engagement remains a material commercial priority.
Traditional HCP targeting answers who matters. Next best action HCP models answer a more consequential question: what should happen next?
A useful NBA recommendation combines signals such as:
The output isn't another score. It's a decision: prioritise HCP X, lead with a digital touchpoint, reinforce the new clinical evidence and schedule an in-person follow-up. That's the difference between HCP intelligence and commercial action, and it's where commercial analytics in pharma earns its keep: not by generating more insight, but by embedding it into decisions commercial teams make daily.
AI for next best action in pharma shouldn't just predict which HCP is likely to prescribe. It should connect prediction to intervention, through a closed loop:
The last-mile challenge is what can prevent an NBA recommendation from becoming a field action: the recommendation may exist but never reach the rep or manager in a form they can act on within their existing workflow.
That is the gap HCPPulse from Polestar Analytics is built to close, from generating the prioritized recommendation through to placing it in the rep's daily workflow.
See HCPPulse in action:
HCPPulse brings together CRM engagement history, prescription patterns, patient-journey insight and third-party healthcare data into a single HCP profile. It then turns that profile into field-ready output: identifying high-priority HCPs, recommending an engagement channel, giving reps personalised guidance, building a prioritised action queue and optimising field routes.
These capabilities sit within Polestar Analytics' broader pharmaceutical analytics solution, where HCP intelligence and pharma next best action recommendations connect directly to commercial execution. The difference from a standard dashboard is the last mile: a dashboard tells a territory manager an HCP is high value; HCPPulse turns that into a ranked field priority, with a reason and an action attached.
The strongest next best action for HCP engagement systems don't replace the rep. They reduce the work required before a rep can have a useful conversation. For a territory manager, that's the shift from "here is your target list" to "here are the HCPs that matter now, why and what your team should do next."
HCPPulse operationalises this through an intelligent action queue and a strategy layer that translates commercial intent into P1–P4 HCP priorities. For field teams, this becomes a resource-allocation mechanism: reps have finite time, while HCPs differ in needs, responsiveness and commercial potential.
The connection between prioritisation and execution is explored further in Field Force Effectiveness in Pharma.
Leaders should evaluate next best action in pharma across:
At minimum: reliable HCP identity, CRM engagement, prescribing or claims signals, channel behaviour and relevant commercial context. Value comes from connecting these to a decision, not accumulating more data.
They answer different questions. Segmentation groups HCPs and assigns priority tiers, while next best action decides what to do with an individual HCP, through which channel, and when. In practice, segmentation is an input into the next best action decision layer, not a substitute for it. For a deeper look at the input side, see AI-Driven HCP Segmentation in Pharma.
They must be, or reps won't use them. Every recommendation should show the signals behind the ranking, why that channel was chosen, and how confident the model is. HCPPulse is built this way: each action in the queue carries its rationale, so the rep sees the priority HCP and the reason it surfaced.
Against business outcomes and workflow adoption, not model accuracy alone. The real test is whether strategy changes translate quickly into better priorities, field actions and measurable results.